Efficacy and safety of chloroquine plus prednisone for the treatment of autoimmune hepatitis in a randomized trial
Lydia T de Moraes Falcão, Debora R B Terrabuio, Marcio A Diniz, Andreia da Silva Evangelista, Fabricio G Souza, Eduardo L R Cancado, Lydia T de Moraes Falcão, Debora R B Terrabuio, Marcio A Diniz, Andreia da Silva Evangelista, Fabricio G Souza, Eduardo L R Cancado
Abstract
Background and aim: Standard treatment for autoimmune hepatitis (AIH) consists of predniso(lo)ne and azathioprine. However, alternative therapy is required for non- or partial responders and in cases of side effects. The aim of this study was to evaluate the treatment outcomes associated with chloroquine plus prednisone in AIH patients.
Methods: Fifty-seven patients were recruited to receive either azathioprine or chloroquine, both with prednisone, in a randomized trial. The primary end-point was complete remission, based on normalization of aminotransferase levels in the first 6 months of treatment plus maintenance for at least 18 months, with minimal or no inflammatory activity in the liver biopsy. Secondary end-points were partial and nonresponse, severe side effects, and treatment withdrawal.
Results: There were no differences between groups regarding clinical, serological, histological, and treatment characteristics at baseline. There were no significant differences in the biochemical response rate (67.7 vs 53.8%, P = 0.41) or the complete remission rate (32.26 vs 15.38%, P = 0.217). However, despite the long study period, the sample size was smaller than that required for a noninferiority study. The mean prednisone dose was similar in both groups. There was a nonsignificantly higher rate of adverse effects and a tendency toward improvement in glycemic and cholesterol profiles in the chloroquine group (P = 0.09 and P = 0.07, respectively).
Conclusions: The combination of chloroquine and prednisone exhibited potentially beneficial effects in AIH patients (https://ClinicalTrials.gov: NCT02463331).
Keywords: antimalarial drug; autoimmune hepatitis; chloroquine; remission.
© 2019 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Figures
References
- Manns MP, Czaja AJ, Gorham JD et al Diagnosis and management of autoimmune hepatitis. Hepatology. 2010; 51: 2193–213.
- European Association for the Study of the Liver . EASL clinical practice guidelines: autoimmune hepatitis. J. Hepatol. 2015; 63: 971–1004.
- Johnson PJ, McFarlane IG, Williams R. Azathioprine for long‐term maintenance of remission in autoimmune hepatitis. N. Engl. J. Med. 1995; 333: 958–63.
- Czaja AJ. Review article: permanent drug withdrawal is desirable and achievable for autoimmune hepatitis. Aliment. Pharmacol. Ther. 2014; 39: 1043–58.
- Manns MP, Woynarowski M, Kreisel W et al Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010; 139: 1198–206.
- Zachou K, Gatselis NK, Arvaniti P et al A real‐world study focused on the long‐term efficacy of mycophenolate mofetil as first‐line treatment of autoimmune hepatitis. Aliment. Pharmacol. Ther. 2016; 43: 1035–47.
- Rubin JN, Te HS. Refractory autoimmune hepatitis: beyond standard therapy. Dig. Dis. Sci. 2016; 61: 1–6.
- Beretta‐Piccoli BT, Mieli‐Vergani G, Vergani D. Autoimmune hepatitis: standard treatment and systematic review of alternative treatments. World J. Gastroenterol. 2017; 23: 6030–48.
- Solomon VR, Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur. J. Pharmacol. 2009; 625: 220–33.
- Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat. Rev. Rheumatol. 2012; 8: 522–33.
- Van Vollenhoven RF, Mosca M, Bertsias G et al Treat‐to‐target in systemic lupus erythematosus: recommendations from an international task force. Ann. Rheum. Dis. 2014; 73: 958–67.
- Da Silva JC, Mariz HA, Da Rocha LF et al Hydroxychloroquine decreases Th17‐related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics (Sao Paulo). 2013; 68: 766–71.
- Mucenic M, De Mello ES, Cançado ELR. Chloroquine for the maintenance of remission of autoimmune hepatitis: results of a pilot study. Arq. Gastroenterol. 2005; 42: 249–55.
- Terrabuio DRB, Diniz MA, Falcão LTM et al Chloroquine is effective for maintenance of remission in autoimmune hepatitis: controlled, double‐blind, randomized trial. Hepatol. Commun. 2018; 3: 116–28.
- Alvarez F, Berg PA, Bianchi FB et al International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 1999; 31: 929–38.
- Trotti A, Colevas AD, Setser A et al CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin. Radiat. Oncol. 2003; 13: 176–81.
- Czaja AJ, Souto EO, Bittencourt PL et al Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J. Hepatol. 2002; 37: 302–8.
- Chen Z‐X, Shao J‐G, Shen Y et al Prognostic implications of antibodies to soluble liver antigen in autoimmune hepatitis. Medicine (Baltimore). 2015; 94: e953.
- Kirstein MM, Metzler F, Geiger E et al Prediction of short‐ and long‐term outcome in patients with autoimmune hepatitis. Hepatology. 2015; 62: 1524–35.
- Czaja AJ, Carpenter HA, Moore SB. Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4. Liver Int. 2006; 26: 552–8.
- Lamers MMH, van Oijen MGH, Pronk M, Drenth JPH. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J. Hepatol. 2010; 53: 191–8.
- Czaja AJ. Current and prospective pharmacotherapy for autoimmune hepatitis. Expert Opin. Pharmacother. 2014; 15: 1715–36.
- Hage MP, Al‐Badri MR, Azar ST. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti‐inflammatory role. Ther. Adv. Endocrinol. Metab. 2014; 5: 77–85.
- Borba EF, Bonfá E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J. Rheumatol. 2001; 28: 780–5.
- Kavanaugh A, Adams‐Huet B, Jain R, Denke M, McFarlin J. Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double‐blind, randomized, placebo‐controlled, pilot study in patients with systemic lupus erythematosus. J. Clin. Rheumatol. 1997; 3: 3–8.
- Ruiz‐Irastorza G, Ramos‐Casals M, Brito‐Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. Dis. 2010; 69: 20–8.
- Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016; 123: 1386–94.
Source: PubMed